Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AG-013726 · 1 trial · 1 indication
Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as \>=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.
| Arm | Type | Description |
|---|---|---|
| B | ACTIVE_COMPARATOR | bevacizumab 5 mg/kg every 2 weeks + FOLFOX |
| C | EXPERIMENTAL | AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX |
| A | EXPERIMENTAL | AG-013736 5 mg bid starting dose + FOLFOX |
| Name | Type | Description |
|---|---|---|
| bevacizumab | DRUG | bevacizumab 5 mg/kg every 2 weeks |
| AG-013726 | DRUG | AG-013726 5 mg bid every 2 weeks |
| AG-013736 (axitinib) | DRUG | AG-013736 5 mg bid starting dose |
Inclusion Criteria: * (Phase 1) Patients with any solid/GI tumor who have had no more than 1 previous chemotherapy for greater than 3 months prior to enrollment * (Phase 2) Patients with locally advanced or metastatic colorectal cancer (CRC) previously untreated with any systemic therapy. * Patient...
AG-013726 is an investigational small molecule being studied for the treatment of colorectal neoplasms, specifically in patients with metastatic colorectal cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AG-013726 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for colorectal neoplasms.
AG-013726 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of colorectal neoplasms, including metastatic colorectal cancer.
AG-013726 has been studied in one completed Phase 1 clinical trial, NCT00460603, which evaluated the drug in combination with chemotherapy and bevacizumab in patients with metastatic colorectal cancer. The trial enrolled 187 participants in the United States.
AG-013726 is the drug name provided, while the clinical trial NCT00460603 refers to AG-013736. The relationship between these two names is not specified, and they may refer to the same compound or different compounds.